Interpace Biosciences, Inc. – OTC:IDXG
Interpace Biosciences stock price today
Interpace Biosciences stock price monthly change
Interpace Biosciences stock price quarterly change
Interpace Biosciences stock price yearly change
Interpace Biosciences key metrics
Market Cap | 4.47M |
Enterprise value | 1.56M |
P/E | -0.79 |
EV/Sales | 0.03 |
EV/EBITDA | -0.06 |
Price/Sales | 0.08 |
Price/Book | -0.07 |
PEG ratio | 0.01 |
EPS | 0.22 |
Revenue | 40.66M |
EBITDA | 3.63M |
Income | 919K |
Revenue Q/Q | 4.54% |
Revenue Y/Y | 13.89% |
Profit margin | -54.58% |
Oper. margin | -22.87% |
Gross margin | 51.83% |
EBIT margin | -22.87% |
EBITDA margin | 8.95% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInterpace Biosciences stock price history
Interpace Biosciences stock forecast
Interpace Biosciences financial statements
| Jun 2023 | 11.02M | 175K | 1.59% |
|---|---|---|---|
| Sep 2023 | 9.07M | -614K | -6.76% |
| Dec 2023 | 10.28M | 890K | 8.66% |
| Mar 2024 | 10.27M | 468K | 4.56% |
| 2025 | 54.44M | 0 |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 15942000 | 78.14M | 490.2% |
|---|---|---|---|
| Sep 2023 | 14250000 | 76.93M | 539.86% |
| Dec 2023 | 13021000 | 28.15M | 216.24% |
| Mar 2024 | 12142000 | 26.74M | 220.28% |
| Jun 2023 | 411K | -228K | -700K |
|---|---|---|---|
| Sep 2023 | 1.10M | 348K | -1.5M |
| Dec 2023 | 1.14M | -142K | -2.53M |
| Mar 2024 | -58K | -28K | -600K |
Interpace Biosciences alternative data
| Aug 2023 | 94 |
|---|---|
| Sep 2023 | 94 |
| Oct 2023 | 94 |
| Nov 2023 | 94 |
| Dec 2023 | 94 |
| Jan 2024 | 94 |
| Feb 2024 | 94 |
| Mar 2024 | 94 |
| Apr 2024 | 94 |
| May 2024 | 108 |
| Jun 2024 | 108 |
| Jul 2024 | 108 |
Interpace Biosciences other data
| Period | Buy | Sel |
|---|---|---|
| Feb 2021 | 82100 | 0 |
| Mar 2021 | 84400 | 0 |
| May 2021 | 10855 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BURNELL THOMAS W. director, officer.. | Common Stock | 10,855 | N/A | N/A | ||
Purchase | KAMIN PETER | Common Stock | 42,200 | $3.08 | $129,976 | ||
Purchase | KAMIN PETER | Common Stock | 42,200 | N/A | N/A | ||
Purchase | KAMIN PETER | Common Stock | 41,050 | $3.17 | $130,129 | ||
Purchase | KAMIN PETER | Common Stock | 41,050 | N/A | N/A | ||
Option | EARLY JAMES other: Former Chief Financial O.. | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | EARLY JAMES other: Former Chief Financial O.. | Common Stock | 5,000 | N/A | N/A | ||
Option | RICHARD GREGORY officer: Chief Commerical Officer | Restricted Stock Units | 2,000 | N/A | N/A | ||
Option | RICHARD GREGORY officer: Chief Commerical Officer | Common Stock | 2,000 | N/A | N/A | ||
Sale | MELILLO GERALD R JR officer: President, Sales Servi.. | Common Stock | 1,748 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q3 2020 21 Jan 2021 | Q3 2020 Earnings Call Transcript |
| Q2 2020 21 Oct 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 25 Jun 2020 | Q1 2020 Earnings Call Transcript |
| Q3 2019 14 Nov 2019 | Q3 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Thomas W. Burnell Ph.D. (1963) Pres, Chief Executive Officer & Director | $425,000 |
-
What's the price of Interpace Biosciences stock today?
One share of Interpace Biosciences stock can currently be purchased for approximately $0.88.
-
When is Interpace Biosciences's next earnings date?
Unfortunately, Interpace Biosciences's (IDXG) next earnings date is currently unknown.
-
Does Interpace Biosciences pay dividends?
No, Interpace Biosciences does not pay dividends.
-
How much money does Interpace Biosciences make?
Interpace Biosciences has a market capitalization of 4.47M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.31% to 40.21M US dollars.
-
What is Interpace Biosciences's stock symbol?
Interpace Biosciences, Inc. is traded on the OTC under the ticker symbol "IDXG".
-
What is Interpace Biosciences's primary industry?
Company operates in the Healthcare sector and Diagnostics & Research industry.
-
How do i buy shares of Interpace Biosciences?
Shares of Interpace Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Interpace Biosciences's key executives?
Interpace Biosciences's management team includes the following people:
- Dr. Thomas W. Burnell Ph.D. Pres, Chief Executive Officer & Director(age: 62, pay: $425,000)
-
How many employees does Interpace Biosciences have?
As Jul 2024, Interpace Biosciences employs 108 workers, which is 15% more then previous quarter.
-
When Interpace Biosciences went public?
Interpace Biosciences, Inc. is publicly traded company for more then 27 years since IPO on 19 May 1998.
-
What is Interpace Biosciences's official website?
The official website for Interpace Biosciences is interpace.com.
-
Where are Interpace Biosciences's headquarters?
Interpace Biosciences is headquartered at Morris Corporate Center 1, Building C, 300 Interpace Parkway, Parsippany, NEW JERSEY.
-
How can i contact Interpace Biosciences?
Interpace Biosciences's mailing address is Morris Corporate Center 1, Building C, 300 Interpace Parkway, Parsippany, NEW JERSEY and company can be reached via phone at +1 412 224 6100.
Interpace Biosciences company profile:
Interpace Biosciences, Inc.
interpace.comOTC
147
Diagnostics & Research
Healthcare
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Parsippany, NEW JERSEY 07054
CIK: 0001054102
ISIN: US46062X3035
CUSIP: 46062X303
